Table 1. . Patient and lesion characteristics for discovery and validation phases.

Patient/lesion characteristic	Discovery	Biological validation
	Lynch	Sporadic	Lynch
Normal mucosa:
n	18	35	23
Definite LS	15 (83%)	n/a	13 (57%)
Age, median (IQR)	53 (44.8–62.5)	64 (53.5–71.5)	50 (37.5–57)
Sex, % female	61%	49%	57%
Advanced adenoma:
n	18	38	39
Definite LS	10 (56%)	n/a	26 (67%)
Age, median (IQR)	57 (53.3–66.3)	64.5 (56–76.3)	59 (50.5–69)
Sex, % female	33%	40%	59%
Site, % proximal	55%	76%	51%
Tubular adenoma	18	13	37
Sessile serrated polyp	0	25	2
Adenocarcinoma:
n	17	36	26
Definite LS	12 (71%)	n/a	14 (54%)
Age, median (IQR)	59 (54–71)	68.5 (57.8–80.5)	46.5 (36.5–58.8)
Sex, % female	41%	50%	46%
Site, % proximal	6159%	47%	46%

IQR: Interquartile range; LS: Lynch syndrome; n: Number of patients.